Login to Your Account



Oricula's otoprotective drug could bring back aminoglycoside use

By Jennifer Boggs
Managing Editor

Friday, August 12, 2016

While its name obviously reflects its work in the field of hearing loss, Oricula Therapeutics Inc.'s biggest impact could actually be in the antibiotics space, focusing its efforts amid the recent global call to action on tackling antimicrobial resistance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription